TY - JOUR
T1 - Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis
AU - International EEsAI Study Group
AU - Schoepfer, Alain M.
AU - Hirano, Ikuo
AU - Coslovsky, Michael
AU - Roumet, Marie C.
AU - Zwahlen, Marcel
AU - Kuehni, Claudia E.
AU - Hafner, David
AU - Alexander, Jeffrey A.
AU - Dellon, Evan S.
AU - Gonsalves, Nirmala
AU - Leung, John
AU - Bussmann, Christian
AU - Collins, Margaret H.
AU - Newbury, Robert O.
AU - Smyrk, Thomas Christopher
AU - Woosley, John T.
AU - Yang, Guang Yu
AU - Romero, Yvonne
AU - Katzka, David A
AU - Furuta, Glenn T.
AU - Gupta, Sandeep K.
AU - Aceves, Seema S.
AU - Chehade, Mirna
AU - Spergel, Jonathan M.
AU - Falk, Gary W.
AU - Meltzer, Brian A.
AU - Comer, Gail M.
AU - Straumann, Alex
AU - Safroneeva, Ekaterina
AU - Achem, Sami R.
AU - Arora, Amindra S.
AU - Alpan, Oral
AU - Armstrong, David
AU - Attwood, Stephen E.
AU - Butterfield, Joseph H
AU - Crowell, Michael D
AU - Enders, Felicity T.
AU - Fleischer, David E
AU - Foxx-Orenstein, Amy Elisabeth
AU - Harris, Lucinda A
AU - Kita, Hirohito
AU - Krishna, Murli
AU - Lee, James J
AU - Locke, Giles Richard III
AU - Murray, Joseph A.
AU - Nguyen, Cuong C.
AU - Pasha, Shabana F.
AU - Ramirez, Francisco C.
AU - Wu, Tsung Teh
AU - Yost, Kathleen J.
N1 - Funding Information:
Members of the International EEsAI study group participating in data collection (in alphabetical order): Sami R. Achem (Mayo Clinic, Jacksonville, FL), Amindra S. Arora (Mayo Clinic, Rochester, MN), Oral Alpan (O&O Alpan, LLC, Section on Immunopathogenesis, Fairfax, VA), David Armstrong (McMaster University, Hamilton, Canada), Stephen E. Attwood (North Tyneside Hospital, North Shields, UK), Joseph H. Butterfield (Mayo Clinic, Rochester, MN), Michael D. Crowell (Mayo Clinic, Scottsdale, AZ), Kenneth R. DeVault (Mayo Clinic, Jacksonville, FL), Eric Drouin (CHU Sainte-Justine, Montreal, Canada), Benjamin Enav (Pediatric Gastroenterology of Northern Virginia, Fairfax, VA), Felicity T. Enders (Mayo Clinic, Rochester, MN), David E. Fleischer (Mayo Clinic, Scottsdale, AZ), Amy Foxx-Orenstein (Mayo Clinic, Scottsdale, AZ), Dawn L. Francis (Mayo Clinic, Jacksonville, FL), Gordon H. Guyatt (McMaster University, Hamilton, Canada), Lucinda A. Harris (Mayo Clinic, Scottsdale, AZ), Amir F. Kagalwalla (Northwestern University Feinberg School of Medicine, Chicago, IL), Hirohito Kita (Mayo Clinic, Rochester, MN), Murli Krishna (Mayo Clinic, Jacksonville, FL), James J. Lee (Mayo Clinic, Scottsdale, AZ), John C. Lewis (Mayo Clinic, Scottsdale, AZ), Kaiser Lim (Mayo Clinic, Rochester, MN), G. Richard Locke III (Mayo Clinic, Rochester, MN), Joseph A. Murray (Mayo Clinic, Rochester, MN), Cuong C. Nguyen (Mayo Clinic, Scottsdale, AZ), Diana M. Orbelo (Mayo Clinic, Rochester, MN), Shabana F. Pasha (Mayo Clinic, Scottsdale, AZ), Francisco C. Ramirez (Mayo Clinic, Scottsdale, AZ), Javed Sheikh (Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA), Sarah B. Umar (Mayo Clinic, Scottsdale, AZ), Catherine R. Weiler (Mayo Clinic, Rochester, MN), John M. Wo (Indiana University, Indianapolis, IN), Tsung-Teh Wu (Mayo Clinic, Rochester, MN), and Kathleen J. Yost (Mayo Clinic, Rochester, MN).
Funding Information:
Funding Supported by the following grants from the Swiss National Science Foundation (grant no. 32003B_135665/1 to A.M.S., A.S., C.K., and M.Z. and 32473B_160115/1 to A.M.S.), AstraZeneca AG, Switzerland, Adare Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Germany, Glaxo Smith Kline AG, Nestlé S. A., Switzerland, Receptos Inc, Regeneron Pharmaceuticals Inc, and The International Gastrointestinal Eosinophil Researchers (TIGER). The data for score responsiveness were generated by Aptalis Pharma, Inc (currently owned by Adare Pharmaceuticals, Inc).
Publisher Copyright:
© 2019 AGA Institute
PY - 2019/7
Y1 - 2019/7
N2 - Background & Aims: Eosinophilic esophagitis (EoE) is assessed endoscopically (endoscopic activity), based on grades of edema, rings, exudates, furrows, and strictures (EREFS). We examined variations in endoscopic assessments of severity, developed and validated 3 EREFS-based scoring systems, and assessed responsiveness of these systems using data from a randomized placebo-controlled trial of patients with EoE. Methods: For the development set, 5 gastroenterologists reviewed EREFS findings from 266 adults with EoE and provided endoscopist global assessment scores (EndoGA, scale of 0 to 10); variation (ΔEndoGA) was assessed using linear regression. We evaluated simple scores (features given arbitrary values from 0 to 3) and developed 2 scoring systems (adjusted score range, 0–100). We then fitted our linear regression model with mean EndoGA to data from 146 adults recruited in centers in Switzerland and the United States between April 2011 and December 2012. For the validation set, we collected data from 120 separate adults (recruited in centers in Switzerland and the United States between May 2013 and July 2014), assessing regression coefficient-based scores using Bland-Altman method. We assessed the responsiveness of our scoring systems using data from a randomized trial of patients with EoE given fluticasone (n=16) or placebo (n=8). Results: The distribution of EndoGA values differed among endoscopists (mean ΔEndoGA, 2.6±1.8; range 0–6.6). We developed 2 regression-based scoring systems to assess overall and proximal and distal esophageal findings; variation in endoscopic features accounted for more than 90% of the mean EndoGA variation. In the validation group, differences between mean EndoGA and regression-based scores were small (ranging from –4.70 to 2.03), indicating good agreement. In analyses of data from the randomized trial, the baseline to end of study change in patients given fluticasone was a reduction of 24.3 in simple score (reduction of 4.6 in patients given placebo, P=.052); a reduction of 23.5 in regression-based overall score (reduction of 6.56 in patients given placebo, P=.12), and a reduction of 23.8 (reduction of 8.44 in patients given placebo, P=.11). Conclusion: Assessments of endoscopic activity in patients with EoE vary among endoscopists. In an analysis of data from a randomized controlled trial, we found that newly developed scoring systems are no better than simple scoring system in detecting changes in endoscopic activity. These results support the use of a simple scoring system in evaluation of endoscopic activity in patients with EoE. clinicaltrials.gov
AB - Background & Aims: Eosinophilic esophagitis (EoE) is assessed endoscopically (endoscopic activity), based on grades of edema, rings, exudates, furrows, and strictures (EREFS). We examined variations in endoscopic assessments of severity, developed and validated 3 EREFS-based scoring systems, and assessed responsiveness of these systems using data from a randomized placebo-controlled trial of patients with EoE. Methods: For the development set, 5 gastroenterologists reviewed EREFS findings from 266 adults with EoE and provided endoscopist global assessment scores (EndoGA, scale of 0 to 10); variation (ΔEndoGA) was assessed using linear regression. We evaluated simple scores (features given arbitrary values from 0 to 3) and developed 2 scoring systems (adjusted score range, 0–100). We then fitted our linear regression model with mean EndoGA to data from 146 adults recruited in centers in Switzerland and the United States between April 2011 and December 2012. For the validation set, we collected data from 120 separate adults (recruited in centers in Switzerland and the United States between May 2013 and July 2014), assessing regression coefficient-based scores using Bland-Altman method. We assessed the responsiveness of our scoring systems using data from a randomized trial of patients with EoE given fluticasone (n=16) or placebo (n=8). Results: The distribution of EndoGA values differed among endoscopists (mean ΔEndoGA, 2.6±1.8; range 0–6.6). We developed 2 regression-based scoring systems to assess overall and proximal and distal esophageal findings; variation in endoscopic features accounted for more than 90% of the mean EndoGA variation. In the validation group, differences between mean EndoGA and regression-based scores were small (ranging from –4.70 to 2.03), indicating good agreement. In analyses of data from the randomized trial, the baseline to end of study change in patients given fluticasone was a reduction of 24.3 in simple score (reduction of 4.6 in patients given placebo, P=.052); a reduction of 23.5 in regression-based overall score (reduction of 6.56 in patients given placebo, P=.12), and a reduction of 23.8 (reduction of 8.44 in patients given placebo, P=.11). Conclusion: Assessments of endoscopic activity in patients with EoE vary among endoscopists. In an analysis of data from a randomized controlled trial, we found that newly developed scoring systems are no better than simple scoring system in detecting changes in endoscopic activity. These results support the use of a simple scoring system in evaluation of endoscopic activity in patients with EoE. clinicaltrials.gov
KW - Esophagus
KW - Index
KW - Instrument
KW - Variability in Endoscopic Assessment
UR - http://www.scopus.com/inward/record.url?scp=85066067214&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066067214&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2018.11.032
DO - 10.1016/j.cgh.2018.11.032
M3 - Article
C2 - 30476587
AN - SCOPUS:85066067214
SN - 1542-3565
VL - 17
SP - 1477-1488.e10
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 8
ER -